Notice of Results

RNS Number : 5404J

Avacta Group PLC

08 April 2015

 

Avacta Group plc

("Avacta" or "the Group")

Notice of Results

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare will be reporting its interim results for the six months ended 31 January 2015 on Tuesday 28 April 2015.

Alastair Smith, CEO and Tim Sykes, FD will be hosting a briefing for analysts on Tuesday 28 April 2015 at 9.30am at the London Capital Club, 15 Abchurch Lane, London, EC4N 7BW.

For more information or to register to attend the briefing contact Walbrook PR (contact details below).

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer	Tel:  [phone] www.avacta.com
Numis Securities Limited     Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking	Tel:  [phone] www.numiscorp.com
Media Enquiries Walbrook PR Ltd Mike Wort / Anna Dunphy	Tel: [phone] [e-mail]

About Avacta Group plc - www.avacta.com Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.  Avacta operates through three divisions: Avacta Life Sciences www.avactalifesciences.com Novel engineered antibody replacements called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development. Avacta Animal Health www.avactaanimalhealth.com Veterinary diagnostics reference laboratory and diagnostic kit provider. Avacta Analytical www.avactaanalytical.com High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

 

END

 

 

NORSSFFIWFISEIL